Cargando…

A Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Immunoglobulin G Assay: A Robust Method for Evaluation of Vaccine Immunogenicity Using an Established Correlate of Protection

As the COVID-19 pandemic continues, variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge. Immunogenicity evaluation of vaccines and identification of correlates of protection for vaccine effectiveness is critical to aid the development of vaccines against emerg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Mingzhu, Cloney-Clark, Shane, Feng, Sheau-line, Parekh, Anand, Gorinson, Drew, Silva, David, Skonieczny, Paul, Wilson, Adjele, Kalkeri, Raj, Woo, Wayne, Cai, Miranda R., Fries, Louis, Glenn, Greg, Plested, Joyce S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383018/ https://www.ncbi.nlm.nih.gov/pubmed/37512961 http://dx.doi.org/10.3390/microorganisms11071789

Ejemplares similares

Severe Acute Respiratory Syndrome Coronavirus 2 Receptor (Human Angiotensin-Converting Enzyme 2) Binding Inhibition Assay: A Rapid, High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation
por: Plested, Joyce S., et al.
Publicado: (2023)

Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373
por: Alves, Katia, et al.
Publicado: (2023)

Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373
por: Alves, Katia, et al.
Publicado: (2023)

NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4(+) and CD8(+) T cell responses
por: Rydyznski Moderbacher, Carolyn, et al.
Publicado: (2022)

Immunogenicity of NVX-CoV2373 in PREVENT-19: A Phase 3, Randomized, Placebo-Controlled Trial in Adults in the United States and Mexico
por: Áñez, Germán, et al.
Publicado: (2023)

Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents
por: Áñez, Germán, et al.
Publicado: (2023)

Strong CD4(+) T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination
por: Fries, Louis, et al.
Publicado: (2023)

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial
por: Mallory, Raburn M, et al.
Publicado: (2022)

A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults
por: Kulkarni, Prasad S., et al.
Publicado: (2023)

2753. Induction of Broadly Cross-Reactive Immune Responses Against A(H3N2) Airuses: Results of a Phase 2 Trial of a Novel Recombinant Hemagglutinin Saponin-Adjuvanted Nanoparticle Seasonal Influenza Vaccine
por: Shinde, Vivek, et al.
Publicado: (2019)

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
por: Keech, Cheryl, et al.
Publicado: (2020)

Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M–Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine
por: Shinde, Vivek, et al.
Publicado: (2020)

Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial
por: Madhi, Shabir A, et al.
Publicado: (2022)

LB19. Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Illness (LRTI) in Infants
por: Fries, Louis, et al.
Publicado: (2018)

Effect of D614G Spike Variant on Immunoglobulin G, M, or A Spike Seroassay Performance
por: Klumpp-Thomas, Carleen, et al.
Publicado: (2020)

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial
por: Formica, Neil, et al.
Publicado: (2021)

Robustness of STDP to spike timing jitter
por: Cui, Yihui, et al.
Publicado: (2018)

Robust computation with rhythmic spike patterns
por: Frady, E. Paxon, et al.
Publicado: (2019)

The geometry of robustness in spiking neural networks
por: Calaim, Nuno, et al.
Publicado: (2022)

Immunogenicity of the spike glycoprotein of Bat SARS-like coronavirus
por: Hou, Yu-xuan, et al.
Publicado: (2010)

SARS-CoV-2 Spike Pseudoviruses: A Useful Tool to Study Virus Entry and Address Emerging Neutralization Escape Phenotypes
por: Kalkeri, Raj, et al.
Publicado: (2021)

Robustness of Spike Deconvolution for Neuronal Calcium Imaging
por: Pachitariu, Marius, et al.
Publicado: (2018)

Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study
por: Kulkarni, Prasad S., et al.
Publicado: (2023)

Identification of immunogenic determinants of the spike protein of SARS-like coronavirus
por: Zhou, Peng, et al.
Publicado: (2013)

2777. Live-Attenuated Vaccine Against RSV Generates Robust Cellular and Humoral Immune Responses
por: Mueller, Steffen, et al.
Publicado: (2019)

Immunogenic properties of immunoglobulin superfamily members within complex biological networks
por: Odales, Josué, et al.
Publicado: (2020)

Stimulatory Effect of CMV Immunoglobulin on Innate Immunity and on the Immunogenicity of CMV Antigens
por: Deml, Ludwig, et al.
Publicado: (2021)

2637. Third Trimester Immunization with an Respiratory Syncytial Virus F Protein Vaccine for the Prevention of RSV Lower Respiratory Tract Infection in Infants
por: Fries, Louis F, et al.
Publicado: (2019)

Toward robust and scalable deep spiking reinforcement learning
por: Akl, Mahmoud, et al.
Publicado: (2023)

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
por: Tian, Jing-Hui, et al.
Publicado: (2021)

XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants
por: Patel, Nita, et al.
Publicado: (2023)

Spike-directed vaccination elicits robust spike-specific T-cell response, including to mutant strains
por: Stanojevic, Maja, et al.
Publicado: (2022)

Immunogenicity of a recombinant coronavirus spike glycoprotein expressed in transgenic plants
por: Escribano, J.M., et al.
Publicado: (2000)

Modeling coronavirus spike protein dynamics: implications for immunogenicity and immune escape
por: Kunkel, Genevieve, et al.
Publicado: (2021)

A polymeric immunoglobulin—antigen fusion protein strategy for enhancing vaccine immunogenicity
por: Webster, Gina R., et al.
Publicado: (2018)

Structural and computational design of a SARS-CoV-2 spike antigen with improved expression and immunogenicity
por: Williams, James A., et al.
Publicado: (2023)

A Spiking Neural Network Framework for Robust Sound Classification
por: Wu, Jibin, et al.
Publicado: (2018)

Memory-inspired spiking hyperdimensional network for robust online learning
por: Zou, Zhuowen, et al.
Publicado: (2022)

Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial
por: Toback, Seth, et al.
Publicado: (2022)

Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein
por: Al-amri, Sawsan S., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9dfifkfegr6u144tqicdo6cdss